Skip to main content

Table 1 Patients’ characteristics

From: Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Variables  
Median age, years (range) 71.2 (52.5–82.9)
Cycles of docetaxel, cycles (range) 9 (1–55)
Use of enzalutamide, n (%) 35 (72.9)
Use of abiraterone acetate, n (%) 26 (54.1)
Median aBSI, %, (range) 3.5 (0.0–12.9)
Median baseline PSA, ng/mL (range) 152.1 (1.6–3564.0)
Median baseline Hb, g/dL (range) 11.0 (8.1–14.2)
Median baseline LDH, IU/L (range) 262 (124–3509)
Median baseline ALP, IU/L (range) 414 (111–3653)
Lymph node metastasis, n (%) 32 (66.6)
Visceral metastasis, n (%) 23 (47.9)
Cycles of cabazitaxel, cycles (range) 4 (1–15)
Median observation period, months (range) 7.2 (0.6–25.0)
Cancer death, n (%) 25 (56.2)
  1. aBSI automated bone scan index, ALP alkaline phosphatase, Hb hemoglobin, LDH lactate dehydrogenase, PSA prostate-specific antigen